CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.
Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .
Resultado final
Communication and dissemination plan: Details on the dissemination strategyand action plan including analysis of stakeholder groups, identification of keyevents and activities
Project Quality Plan (PQP): rules for meetings management, documents naming and storage, deliverables preparation and quality review (se abrirá en una nueva ventana)Project Quality Plan (PQP): rules for meetings management, documents namingand storage, deliverables preparation and quality review
Study initiation package – RISP (se abrirá en una nueva ventana)Study initiation package-RISP (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Midterm recruitment report – PREVALUNG ETOILE (se abrirá en una nueva ventana)Midterm recruitment report-PREVALUNG ETOILE: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Project Management Plan (PMP): organisation, scope of work, Master Plan, Project Action List, risk register (se abrirá en una nueva ventana)Project Management Plan (PMP): organisation, scope of work, Master Plan,Project Action List, risk register
First meeting of the PAB minutes (se abrirá en una nueva ventana)Publication on the performance of PREVALUNG-EU classifiers based on PREVALUNG France and retrospective exploitation of FLEMENGHO, ROBINSCA and SUMMIT. (se abrirá en una nueva ventana)
Publication on the performance of PREVALUNG-EU classifiers based onPREVALUNG France and retrospective exploitation of FLEMENGHO, ROBINSCA and SUMMIT.
Report on the status of posting results in a repository – FLEMENGHO (se abrirá en una nueva ventana)Report on the status of posting results in a repository-FLEMENGHO. Irrespective of the successful completion of the clinical study, summary results must be posted in the applicable registry/ies (where the study was registered) even if the timing of posting of results falls outside of the grant period. The report is to be scheduled for the time results posting is expected or for the last months of the project, whichever comes earlier.
Midterm recruitment report – SUMMIT (se abrirá en una nueva ventana)Midterm recruitment report-SUMMIT: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Management Board charts signed by members (se abrirá en una nueva ventana)Study initiation package – PREVALUNG BIOCEPTION (se abrirá en una nueva ventana)
Prepared before enrolment of the first study participant, the report includes: • Registration number of the clinical study in a registry meeting WHO Registry criteria • Final version of study protocol as approved by the regulator(s) / ethics committee(s) • Regulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Report on the status of posting results in a repository – PREVALUNG (se abrirá en una nueva ventana)Report on the status of posting results in a repository-PREVALUNG. Irrespective of the successful completion of the clinical study, summary results must be posted in the applicable registry/ies (where the study was registered) even if the timing of posting of results falls outside of the grant period. The report is to be scheduled for the time results posting is expected or for the last months of the project, whichever comes earlier.
Midterm recruitment report – PREVALUNG (se abrirá en una nueva ventana)Midterm recruitment report- PREVALUNG: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Midterm recruitment report – ROBINSCA (se abrirá en una nueva ventana)Midterm recruitment report-ROBINSCA: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Report on the traceability of samples and biomarker monitoring (se abrirá en una nueva ventana)Study initiation package – SUMMIT (se abrirá en una nueva ventana)
Study initiation package-SUMMIT (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Prospective technical implementation of the user- friendly Bio-Me filter-cards for the diagnosis of stool dysbiosis (se abrirá en una nueva ventana)Prospective technical implementation of the user- friendly Bio-Me filter-cardsfor the diagnosis of stool dysbiosis
Study initiation package – FLEMENGHO (se abrirá en una nueva ventana)Study initiation package-FLEMENGHO (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Midterm recruitment report – RISP (se abrirá en una nueva ventana)Midterm recruitment report- RISP: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Report and/or publication on the performance of the classifiers and statistics for each classifier and interdependency/interaction in between classifiers (se abrirá en una nueva ventana)Report and/or publication on the performance of the classifiers and statistics foreach classifier and interdependency/interaction in between classifiers
Study initiation package – PREVALUNG ETOILE (se abrirá en una nueva ventana)Study initiation package-PREVALUNG ETOILE (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Study initiation package – ROBINSCA (se abrirá en una nueva ventana)•Study initiation package-ROBINSCA (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Study initiation package – NCL TLHC (se abrirá en una nueva ventana)Study initiation package-NCL TLHC (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Study initiation package – PREVALUNG (se abrirá en una nueva ventana)Study initiation package- PREVALUNG (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)
Report on the status of posting results in a repository – PREVALUNG ETOILE (se abrirá en una nueva ventana)Report on the status of posting results in a repository-PREVALUNG ETOILE. Irrespective of the successful completion of the clinical study, summary results must be posted in the applicable registry/ies (where the study was registered) even if the timing of posting of results falls outside of the grant period. The report is to be scheduled for the time results posting is expected or for the last months of the project, whichever comes earlier.
Midterm recruitment report – FLEMENGHO (se abrirá en una nueva ventana)Midterm recruitment report-FLEMENGHO: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.
Report and/or publication on the validity of all four classifiers (CHIP-LC mutations, innate immunity soluble markers, stool TOPOSCORE, ACBP/DBI, polyamines, αketoglutarate (aKG) metabolites) as assessed with primary academic methodologies versus biotech (se abrirá en una nueva ventana)Report and/or publication on the validity of all four classifiers (CHIP-LCmutations, innate immunity soluble markers, stool TOPOSCORE, ACBP/DBI,polyamines, αketoglutarate (aKG) metabolites) as assessed with primaryacademic methodologies versus biotech devices to predict LC incidence
Visual identity, website and social media: Project branding, introductory projectmaterials, video, infographics, logo are available, website is published andsocial media accounts operative
Publicaciones
Autores:
Everton Santana; Eliana Ibrahimi; Evangelos Ntalianis; Nicholas Cauwenberghs; Tatiana Kuznetsova
Publicado en:
International Journal of Molecular Sciences, Edición 25, 2024, ISSN 1422-0067
Editor:
Multidisciplinary Digital Publishing Institute (MDPI)
DOI:
10.3390/IJMS252312905
Autores:
E. Armand, P. Habert, P.-A. Thomas, X.-B. D'journo, C. Doddoli, A. Fourdrain, D. Trousse, G. Brioude, H. Dutau, I. Hamouda, L. Greillier, A. Mogenet, A. Todesco, J. Tronchetti, J.-B. Lovato, J. Pluvy, O. Mercier, J. Issard, C. Caramella, P. Pradere, D. Boulate
Publicado en:
Journal of Thoracic Oncology, Edición 19, 2025, ISSN 1556-0864
Editor:
Elsevier BV
DOI:
10.1016/J.JTHO.2024.09.866
Autores:
Marine Fidelle, Deborah Suissa, Roxanne Birebent, et al
Publicado en:
Journal for immunotherapy of cancer, Edición 11, 2023, ISSN 2051-1426
Editor:
BMJ Publishing Group Ltd & Society for Immunotherapy of Cancer
DOI:
10.1136/jitc-2023-SITC2023.1510
Autores:
Marine Fidelle, Ai-Ling Tian, Laurence Zitvogel, Guido Kroemer
Publicado en:
Oncoimmunology, Edición 12, 2023
Editor:
Taylor & Francis Group
DOI:
10.1080/2162402X.2023.2224672
Buscando datos de OpenAIRE...
Se ha producido un error en la búsqueda de datos de OpenAIRE
No hay resultados disponibles